AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32066497
Drug: 2 g/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/8 h by continuous infusion (CI)
Trial: 32066497
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day (theoretical highest dose)
Trial: 35226640
Drug: Safety-net antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety-net antibiotic prescription (SNAP) offered to patients with AOM.
Trial: 34987316
Drug: Directional Coronary
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directional Coronary Atherectomy (DCA) followed by drug-coated balloon (DCB) angioplasty
Trial: 32592596
Drug: COC +
RxNorm normalized name: Combination oral contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC + VPR (2 mg/d vilaprisan)
Trial: 32557558
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic therapy alone
Trial: 33840798
Drug: Wheat oral
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat oral immunotherapy (WOIT)
Trial: 36430967
Drug: Melatonin 1
RxNorm normalized name: melatonin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 1 mg/day for 1 year
Trial: 32886189
Drug: 12-month exercise
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month exercise program (weekly supervised step aerobics, circuit exercises, and home training)
Trial: 32938990
Drug: Inhaled prostaglandin-E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled prostaglandin-E2 (PGE2) 100 μg
Trial: 32938990
Drug: Inhaled bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bradykinin (BK) 200 μg
Trial: 32513182
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg∙kg‐1)
Trial: 36563900
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ferric carboxymaltose
Trial: 33367545
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intensive chemotherapy without GO)
Trial: 34498068
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IV acetaminophen
Trial: 34193177
Drug: Sequential finger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential finger task in REs
Trial: 34193177
Drug: Sequential reaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential reaching task in VEs
Trial: 34257678
Drug: Ayurveda drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurveda drug regimen arm II
Trial: 34257678
Drug: Ayurveda drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurveda drug regimen arm I
Trial: 35688677
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (5 mg/kg) and 0.25% bupivacaine (1 mg/kg)
Trial: 35688677
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (1 mg/kg)
Trial: 35688677
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (NaCl)
Trial: 33244709
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact (SSC) combined with maternal singing during music therapy (MT)
Trial: 37315900
Drug: Daily probiotic
RxNorm normalized name: CVS Daily Probiotic Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily probiotic
Trial: 35584639
Drug: Inference-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inference-based cognitive-behavioral therapy (I-CBT)
Trial: 35584639
Drug: Appraisal-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appraisal-based cognitive behavioral therapy (A-CBT)
Trial: 34113093
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (1 mg)
Trial: 32323191
Drug: Rivaroxaban (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (once-daily dosing)
Trial: 32323191
Drug: Rivaroxaban (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (both dosing periods)
Trial: 35265985
Drug: Contezolid 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid 800 mg q12h
Trial: 35265985
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg q12h
Trial: 34880300
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (OT) 24 IU
Trial: 33600918
Drug: Ashwagandha root
RxNorm normalized name: ashwagandha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha root extract (300 mg, twice daily for 8 weeks)
Trial: 32125300
Drug: Individual milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with apical periodontitis of incisors, canines or premolars.
Trial: 32125300
Drug: Individual milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with similar diagnosis and concomitant periodontitis of moderate severity.
Trial: 32125300
Drug: Individual milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with periapical destructive process of molars without periodontitis.
Trial: 33608007
Drug: Targeted lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted lung denervation (TLD) therapy
Trial: 35043428
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus hypomethylating agent (HMA)
Trial: 35043428
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus low-dose cytarabine (LDAC)
Trial: 33743831
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin treatment
Trial: 33743831
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (local treatment)
Trial: 34814867
Drug: cinpanemab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinpanemab, a monoclonal antibody against alpha‐synuclein
Trial: 32054543
Drug: PS +
RxNorm normalized name: Spartan Nash 32 gauge 4 mm Pen Tips + 1C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS + FO (3.3 g/d PS and 450 mg EPA + 1500 mg DHA/d)
Trial: 32054543
Drug: PS (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS (3.3 g/d)
Trial: 32054543
Drug: FO (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FO (450 mg EPA + 1500 mg DHA/d)
Trial: 32776347
Drug: Home parenteral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home parenteral nutrition (PN) or customized intravenous fluid (IVF) support for IBD patients
Trial: 34453208
Drug: Sensor Augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM)
Trial: 32197714
Drug: Mind-body medicine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body medicine use among women with gynecological cancer
Trial: 32197714
Drug: Mind-body medicine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body medicine use among women without gynecological cancer
Trial: 34425226
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg testosterone enanthate per week in sesame oil)
Trial: 35405085
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily)
Trial: 35405085
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m2 once every 3 weeks)
Trial: 33785481
Drug: Dose-dense temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-dense temozolomide plus zotiraciclib
Trial: 33979763
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-102 SL 5.6 mg
Trial: 33979763
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-102 SL 2.8 mg
Trial: 32497023
Drug: l-Arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Arginine supplementation (0.05 mg/kg orally, twice daily)
Trial: 32497023
Drug: l-Arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Arginine supplementation
Trial: 35748393
Drug: Yohimbine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (10 mg, n=17)
Trial: 35748393
Drug: Sulpiride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (200 mg, n=16)
Trial: 39418346
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (AI) alone
Trial: 34240571
Drug: Temperature-controlled radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature-controlled radiofrequency (RF) treatment of the nasal valve
Trial: 34049770
Drug: Intradermal acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acetylcholine (ACh) injection
Trial: 35505467
Drug: Keverprazan 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keverprazan 20 mg once daily
Trial: 34311772
Drug: 15-min talocrural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-min talocrural joint manual therapy plus 30-min specific task-oriented training (group A)
Trial: 33909360
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment at Guanyuan (CV 4), Shuidao (ST 28), Guilai (ST 29), Shenshu (BL 23), and Ciliao (BL 32), disperse-dense wave, 2 Hz/15 Hz frequency, once a day for 10 days per menstrual cycle for 3 menstrual cycles
Trial: 33909360
Drug: Ibuprofen sustained-release
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen sustained-release capsules, 0.3 g each time, once a day for 10 days before menstruation
Trial: 34142293
Drug: Personalized medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized medicine approaches (e.g., patient-derived tumor organoids)
Trial: 32009195
Drug: mepolizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepolizumab (monoclonal antibody to IL-5) as an add-on therapy to glucocorticoid treatment
Trial: 32354681
Drug: Physician-delivered step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Physician-delivered step count prescription
Trial: 35418065
Drug: Daily contact
RxNorm normalized name: CONTACT LENS DAILY CLEANER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily contact testing (DCT) using a rapid Lateral Flow Device (LFD)
Trial: 35320555
Drug: Alpha® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha® ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/30 g), applied two times daily for 4 consecutive courses of chemotherapy
Trial: 35320555
Drug: Placebo ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment, applied two times daily for 4 consecutive courses of chemotherapy
Trial: 35818363
Drug: Baricitinib in
RxNorm normalized name: Product containing baricitinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib in combination with remdesivir therapy (BCT)
Trial: 35818363
Drug: Remdesivir monotherapy
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir monotherapy (RMT)
Trial: 32145827
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel plus ART
Trial: 32145827
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide plus ART
Trial: 32145827
Drug: Intravenous bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bleomycin and vincristine plus ART
Trial: 33037803
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment with 1000 mg IV acetaminophen 20 min before surgery
Trial: 33037803
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with 1000 mg IV acetaminophen after surgery
Trial: 32171038
Drug: NDMC 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDMC 20 mg
Trial: 32171038
Drug: NDMC 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDMC 60 mg
Trial: 32171038
Drug: Clonazepam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 1.5 mg
Trial: 34383681
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment
Trial: 32442673
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration (24 IU intranasally)
Trial: 34369696
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment only (Control group).
Trial: 34496300
Drug: Levonorgestrel 52
RxNorm normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52 mg intrauterine system (IUS) among women with heavy menstrual bleeding
Trial: 34496300
Drug: Levonorgestrel 52
RxNorm normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52 mg intrauterine system (IUS) among users for contraception (comparison group)
Trial: 36260832
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) + Reirradiation (re-RT) 35 Gy in 10 fractions with concurrent BEV IV 10 mg/kg every 2 weeks
Trial: 33499543
Drug: Military Treatment
RxNorm normalized name: typhoid, parenteral, AKD (U.S. military)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Military Treatment Facility Engagement Committee (MTFEC)
Trial: 35344464
Drug: sIPV (Sabin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sIPV (Sabin inactivated poliovirus vaccine)
Trial: 34965953
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment with IL-6 and HGF
Trial: 34965953
Drug: Model based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model based on IL-6, HGF and bevacizumab treatment
Trial: 36058418
Drug: Instructed positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructed positive interaction + intranasal oxytocin
Trial: 36058418
Drug: Control +
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control + intranasal oxytocin
Trial: 34531736
Drug: Oroxylum indicum
RxNorm normalized name: Canarium indicum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oroxylum indicum extract (500 mg, twice daily)
Trial: 34918028
Drug: Efavirenz (EFV1)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV1) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Trial: 34918028
Drug: Efavirenz (EFV2)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV2) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Trial: 34887285
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of zoledronic acid
Trial: 37341961
Drug: Etanercept (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.8 mg/kg)
Trial: 34661664
Drug: High-dose deutetrabenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose deutetrabenazine (up to 48 mg/d)
Trial: 34661664
Drug: Low-dose deutetrabenazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose deutetrabenazine (up to 36 mg/d)
Trial: 34661664
Drug: High-dose deutetrabenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose deutetrabenazine
Trial: 34661664
Drug: Low-dose deutetrabenazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose deutetrabenazine
Trial: 34391242
Drug: Fascial therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy, strength training, and kinesiotaping
Trial: 36450422
Drug: Continue RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue RAS inhibiting therapy
Trial: 36450422
Drug: Discontinue RAS
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discontinue RAS inhibiting therapy
Trial: 36450422
Drug: Continue RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue RAS inhibiting therapy (mechanistic substudy)
Trial: 36450422
Drug: Discontinue RAS
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discontinue RAS inhibiting therapy (mechanistic substudy)
Trial: 33386890
Drug: Grape powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape powder (46 g, equivalent to 252 g fresh grapes)
Trial: 39675209
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine
Trial: 35962939
Drug: Tanezumab 10
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 10 mg (every 8 weeks)
Trial: 35962939
Drug: Tanezumab 5
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 5 mg (every 8 weeks)
Trial: 35962939
Drug: Tramadol (100–300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100–300 mg/day)
Trial: 34491803
Drug: SPR720 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR720 (100 to 2000 mg single doses or 500 to 1500 mg daily doses for 7 or 14 days)
Trial: 32744369
Drug: 0.01% bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% bimatoprost ophthalmic solution
Trial: 33933738
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum calcium levels (per 0.5 mg/dL)
Trial: 32737900
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide at a dose of 20 ppm added to the sweep gas during CPB
Trial: 33611164
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral vinorelbine (mVNR) at a fixed dose of 50 mg × 3
Trial: 33611164
Drug: Standard schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard schedule of vinorelbine (60-80 mg/m2 weekly)
Trial: 33611164
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral vinorelbine (mVNR)
Trial: 34271465
Drug: Indian mustard
RxNorm normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indian mustard (Brassica juncea L.)
Trial: 36223056
Drug: 3 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 monthly injections of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Trial: 36223056
Drug: 1 initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 initial injection of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Trial: 32522420
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HLA)-based vaginal gel, used daily for the first 2 weeks, then 3 times/week until weeks 12-14, increased to 5 times/week for non-responders.
Trial: 32522420
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HLA)-based vaginal gel
Trial: 34213494
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg intravenous injection)
Trial: 34213494
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg intravenous injection)
Trial: 34213494
Drug: Nitroglycerin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.5 μg/kg intravenous injection)